The effects of the Coronavirus pandemic will likely be felt for years to come. Experts say the virus may end up infecting up to 70% of the world’s population, and we may need to have sporadic lockdowns till 2022 to completely eradicate it. It’s safe to say that shutting down most businesses and essentially slowing down consumer spending has had a catastrophic effect on the economy.

With most industries feeling the strain, a lot of businesses have had to let some of their staff go. A record 6 million people filed for unemployment, raising the number of unemployed Americans filing for aid to a whopping 22 million. However, some sectors have thrived amid all the chaos, such as cannabis. Deemed an essential industry by most states that allow marijuana, cannabis businesses have been able to operate unabated during the Coronavirus crisis.

However, cannabis firms in Pennsylvania have run into roadblocks while trying to employ new ‘bud-tenders,’ the staffers who consult with patients. This is despite the fact that more than one in six Pennsylvanians has filed for unemployment since the Coronavirus shutdowns began.

Prospective employees require FBI background checks and drug tests, but most of the offices that process fingerprints are shut down for the time being. “It’s just so unbelievably frustrating. I have five clients with over 100 openings, and there are likely hundreds more that are waiting. These are good-paying jobs, many of which come with health care benefits,” says Harrisburg lawyer Judith Cassel.

She sent a letter to the state Department of Health, requesting a temporary 90-day waiver that would allow job candidates to sign an affidavit stating they don’t have a criminal record. They would also undergo third-party background checks, and any untruthful responses or failing the test will result in immediate termination.

Cassel stressed on the fact that although these measures were indeed useful, these are special times and they require special solutions. “We understand the need for background checks and department oversight on hires during normal circumstances, but these are not normal times. The current process does not rise to the current challenge.”

This problem isn’t restricted to Pennsylvania only. According to an official with Chicago-based marijuana company Cresco Labs, the firm has had a hard time finding people to fill 250 workers in Illinois.

“Under normal circumstances, it would take two to six weeks to get approved,” says Cresco’s Executive Vice President John Sullivan. “But since most state government functions are closed down and a lot of the fingerprint agencies shut, too, the process is stretching out longer and longer.”

Experts believe that cannabis firms like Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) are frustrated that at a time when jobs are being lost, an industry that can employ more people is being held back by a freeze on crucial processes that are a prerequisite for people to secure the available jobs.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced that its common shares are now fully eligible for electronic clearing and settlement through the Depository Trust Company (“DTC”). Champignon’s common shares will continue to trade under the ticker symbol “SHRMF” on the OTC Markets. “We are actively engaged in pursuing new avenues of distribution both in North America and internationally, in order to enhance the ability of larger audiences to participate in the Champignon story, as well as broaden our already robust shareholder base,” Champignon CEO Gareth Birdsall stated in the news release. “With the receipt of DTC eligibility, our common shares will become accessible to United States investors, both retail and institutional – the jurisdiction where many of the important initiatives in psychedelic medicine are emanating and where the company plans to roll out new clinical entities within significant urban population centers.”

To view the full press release, visit http://cnw.fm/jG11h

About Champignon Brands Inc.

Champignon Brands Inc. is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting pre-clinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.Champignonbrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

The past month or two hasn’t been easy for a lot of countries. The Coronavirus pandemic has infected over 1.9 million people worldwide and claimed at least 118,000 lives, and experts say the virus may infect up to 70% of the world’s population. Even before the virus had left South Asia, most of the world was experiencing supply chain disruptions and the economic fallout has only gotten worse as the virus spreads.

Now, with healthcare systems almost collapsing and all but the most essential businesses closed down, the economy is taking quite a hit. The U.S. has become the epicenter of the outbreak, and the federal and state governments have had to provide funds to support healthcare facilities as well as aid to in-need citizens. While such measures are necessary to get through the pandemic, they have thrown most budgets into disarray.

In Washington, for instance, the governor has had to cut funding for a variety of programs so funds can be diverted to the Coronavirus response. This included a cannabis research provision that would have provided $100,000 funding for the University of Washington and Washington State University to “collaborate on cannabis policy, research. And outreach to create frameworks for future studies.”

The budget stated that the research was to explore “impairment due to marijuana use and the correlation between age of use, the dosage of use, and appearance of occurrence of cannabis-induced psychosis,” with a report to the legislature on the development of these frameworks due by December 1.

“These are difficult and challenging times, and we must make difficult and challenging choices. Under normal circumstances, I would not veto bills and budget items that are good policy and smart investments for the state. As everyone knows, these are not normal times,” Washington Governor Jay Inslee said.

“As we address the health crisis, we must also look ahead to ease as much fiscal pain as we can. It is all but certain that we will need to make adjustments to our next budget cycle and we must get started now.”

The governor used his inline veto to trim $235 million from the 2020 supplemental operating budget that the Legislature had approved last month, and the vetoes will trim another $210 million in the state’s next two-year budget. A total of 147 items were vetoed, reducing a total of $445 million in spending over the next three years.

This halt to funding research is likely to disappoint cannabis sector actors like Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) who would like the academic to play a bigger role in shaping cannabis policy in different jurisdictions.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, continues to accelerate its advancements within the psychedelic medicine arena. On Thursday, Champignon Brands announced its plans to acquire a leading Canadian ketamine clinic operator, psychedelic medicine IP aggregator and novel drug discoverer (the “Transaction”) and has entered into a definitive agreement (the “Agreement”) to acquire 100% of AltMed Capital Corp. (“AltMed”). “Founded and operated by Dr. McIntyre, the CRTCE has the human capital and unmatched R&D capabilities, with respect to rapid onset treatments such as ketamine, to revolutionize the treatment of depression, PTSD and substance use disorders,” Gareth Birdsall, CEO of Champignon, said in the news release. “Champignon and AltMed will leverage Dr. McIntyre’s expertise, alongside the CRTCE’s existing SOPs, data-driven research sets and practitioner education modules, to roll out five unique ketamine clinics across Florida, California and the U.S. Eastern Seaboard. Our additional ketamine clinics are projected to be fully operational by Q4 2020. Furthermore, having previously completed funding rounds, our acquisition of AltMed will further bolster our corporate treasury.”

To view the full press release, visit http://cnw.fm/cf2R9

About Champignon Brands Inc.

Champignon Brands Inc. is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting pre-clinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at www.Champignonbrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

Up to now, the restaurant and cannabis industries have had an interesting relationship. When states started legalizing marijuana and the industry really started picking up, restaurants started feeling the strain. As Kevin Burke, General Manager of Denver-based restaurant Morin says, restaurants were already struggling with what was effectively negative fifteen percent unemployment. The growing popularity of cannabis-infused meals strained the already scarce human resource.

“Qualified cooks could walk across the street and get a fifty cents per hour raise, and when cannabis called, they were getting a two, three dollar per hour raise,” he says. He acknowledges that the industry isn’t always employee-centered, saying that the situation helped the restaurant sector to identify some shortcomings and make conditions better for employees.

“It forced restaurants to change for the better in my opinion,” says Burke. And now, as the world faces one of the greatest threats in recent times, the cannabis industry is helping restaurant workers once again.

The Coronavirus first appeared in Wuhan, China late last year and quickly spread to every continent except Antarctica. The virus has infected over 1.4 million individuals worldwide and left at least 87,000 dead. Most governments have taken drastic measures to curb the spread of the virus, and these measures have been anything but kind to the economy.

People are advised to self-isolate and all but the most essential businesses have been shut down for the time being. And while cannabis, fortunately, made the cut, restaurants have had to shut down. In fact, most states with legal marijuana have registered increased marijuana sales, and they have taken additional steps to make sure the industry runs as safely as possible. These include allowing curbside pickups and home deliveries.

Restaurants, on the other hand, have been hit hard, and the employees have suffered most. That’s where the cannabis sector comes in. Toby Ripsom, co-founder of Veritas Cannabis saw a way he could help the restaurant industry, one of the sectors that have been especially affected, and he took it.

“When we sat down as a company to update our HR policies in light of sick days piling up, we wanted to take care of our employees through it but also became attuned of an upcoming struggle to maintain capacity,” he says. His partner, Mike, reached out to a local restaurateur, Max MacKissock, who said he was being forced to lay off more and more employees. “Mike brought that to the rest of the ownership, and we filled a void.”

Additionally, the state has thrown its weight behind the whole thing, making it a lot easier and faster to certify new cannabis employees than it was before. “The Colorado Marijuana Enforcement Division made gaining a badge an expedited, online process. It was previously an in-person application and a tougher hurdle, logistically speaking. The state has been wonderful through this hardship!”

Analysts believe such stories coming out of Colorado give cannabis industry players like Champignon Brands Inc. (CSE: SHRM) (OTC: SHRMF) (FWB: 496) the impetus that they need to think of even more ways to help out during this difficult time of the COVID-19 pandemic.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human-optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, offers a timely line of organic, non-GMO and vegan-certified products. In 2019, Johns Hopkins launched a center for psychedelic research backed by private funders (http://cnw.fm/1lTHD). A recent article discussing the company reads, “The focus of John Hopkin’s studies will be on the affect psychedelics have on behavior, brain function, learning and memory, and the brain’s biology and mood. New therapies and the effectiveness of psilocybin are being explored for opioid addiction, Alzheimer’s disease, post-traumatic stress, post-treatment Lyme disease syndrome, anorexia nervosa and alcohol use related to depression. . . . The use of mushrooms in the health industry is growing in credibility in both scientific and financial sectors, and laws around the use of psilocybin mushrooms and their derivatives are changing. This progress is providing companies such as SHRM the opportunity to support mental health and develop new and improved treatments. The opportunities aren’t only medicinal, so while Champignon is preparing large-scale production for clinical settings, the company is also focused on retail opportunities in the health and wellness market.”

To view the full article, visit http://cnw.fm/u2x6R

About Champignon Brands Inc.

Champignon Brands is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol-use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, Champignon is conducting preclinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or standalone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the company’s website at www.Champignonbrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496), a human optimization sciences company focused on applying novel and natural treatment protocols to address a broad range of disorders and deficiencies with an emphasis on psychedelic medicine, today announced continued augmentation of its Special Advisory Committee with the addition of key individuals experienced in highly regulated industries primed for rapid growth. To this accord, the Company announced the appointment of Jay Kheita, ACPR, to its Special Advisory Committee, where he will help lead the integration of Champignon’s novel and natural treatment protocols into its existing consumer packaged goods (“CPGs”) portfolio. Khetia holds pharmacy licenses in Canada, Australia and England and an honors degree in pharmacy specializing in pharmacognosy, the study of medicinal plants, from the University of Brighton. He is also a founder of AltMed Capital Corp., a leading Canadian psychedelic medicine clinic operator, IP aggregator and solutions provider, and is currently a clinical advisor at the Leslie Dan faculty of pharmacy at the University of Toronto. “We are pleased to welcome Jay to Champignon’s Special Advisory Committee, where he will function as a cornerstone advisor throughout our pursuit to develop and deploy precision medicine focused formulations and delivery systems,” Champignon CEO Gareth Birdsall stated in the news release.

To view the full press release, visit http://cnw.fm/PBj4G

About Champignon Brands Inc.

Champignon Brands Inc. is a research-driven company specializing in the formulation of a suite of medicinal mushrooms health products, as well as novel ketamine, anaesthetics and adaptogenic delivery platforms for the nutritional, wellness and alternative medicine industries. Via its vertically integrated alternative medicine product range, Champignon is pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under a collaborative research agreement with the University of Miami’s Miller School of Medicine, the Company is conducting pre-clinical studies and eventual human clinical trials, with the objective of demonstrating safety and efficacy of the combination of psilocybin and cannabidiol in treating mTBI with PTSD or stand-alone PTSD. Champignon continues to be inspired by sustainability, as its medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For more information, visit the Company’s website at www.Champignonbrands.com.

NOTE TO INVESTORS: The latest news and updates relating to SHRM are available in the company’s newsroom at http://cnw.fm/SHRM

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com